metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
ovarian cancer (OC) ovarian cancer (OC)
versus Standard of Care (SoC)
	niraparib
	ENGOT-OV16/NOVA, 2017 N Engl J Med 2016;375:2154-2164 Lancet Oncol. 2018; 19:1117-1125 NCT01847274	RCT	ovarian cancer (OC)	niraparib (300 mg) once daily as maintenance treatment	placebo	patients with platinum-sensitive, recurrent ovarian cancer with germline BRCA mutation	138 / 65	NA	suggested	suggested 73 % decrease in progression or deaths (PFS)
	olaparib
	SOLO 3, 2020 J Clin Oncol 2020 Apr 10;38(11):1164-1174. NCT02282020	RCT	ovarian cancer (OC)	olaparib 300 mg twice a day	SOC	patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy	178 / 88	NA	safety concern	safety concern with 7 % increase in deaths (OS) (not statistically significant) suggested 38 % decrease in PFS (extension)
	PAOLA-1/ENGOT-ov25, 2019 N Engl J Med 2019 Dec 19;381(25):2416-2428. Eur J Cancer 2022 Oct;174:221-231. NCT02477644	RCT	ovarian cancer (OC)	olaparib plus bevacizumab	placebo plus bevacizumab	patents with newly diagnosed, advanced, high-grade ovarian cancer and were having a response after first-line platinum-taxane chemotherapy plus bevacizumab	537 / 269	NA	suggested	suggested 41 % decrease in PFS (extension)
	SOLO 1, 2018 N. Engl. J. Med. 2018; 379:2495-2505 Lancet Oncol 2021 Dec;22(12):1721-1731. NCT01844986	RCT	ovarian cancer (OC)	olaparib tablets (300 mg twice daily)	placebo	Newly Diagnosed Advanced Ovarian Cancer with a mutation in BRCA1, BRCA2, or both ( BRCA1/2) who had a complete or partial clinical response after platinum-based chemotherapy	260 / 131	NA	suggested	suggested 45 % decrease in deaths (OS) suggested 70 % decrease in progression or deaths (PFS)
	SOLO2/ENGOT-Ov21, 2018 Lancet Oncol 2017;: Lancet Oncol. 2018; 19:1126-1134 Lancet Oncol 2021 May;22(5):620-631. NCT01874353	RCT	ovarian cancer (OC)	olaparib 300 mg in two 150 mg tablets, twice daily	placebo	patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation	196 / 99	NA	suggested	suggested 70 % decrease in progression or deaths (PFS)
	Ledermann, 2012 N Engl J Med 2012;366:1382-92 Lancet Oncol. 2016; 17:1579-1589 Cancer 2016; 122:1844-52 Lancet Oncol. 2014; 15:852-61 Br. J. Cancer 2016; 115:1313-1320 NCT00753545	RCT	ovarian cancer (OC)	olaparib, at a dose of 400 mg twice daily	placebo	maintenance therapy in platinum-sensitive relapsed ovarian cancer	136 / 129	NA	suggested	suggested 65 % decrease in PFS (extension)
	rucaparib
	ARIEL4, 2022 The Lancet Oncology NCT02855944	RCT	ovarian cancer (OC)	oral rucaparib (600 mg twice daily)	chemotherapy (administered per institutional guidelines)	patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation who had received two or more previous chemotherapy regimens who had received two or more previous chemotherapy regimens	-/-	NA	safety concern	safety concern with 31 % increase in deaths (OS) (not statistically significant) suggested 33 % decrease in progression or deaths (PFS)
	ARIEL3, 2017 Lancet 2017; 390:1949-1961 NCT01968213	RCT	ovarian cancer (OC)			after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma	375 / 189	NA	suggested	suggested 64 % decrease in PFS (extension)